ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - dinoprostone - ג'ל - dinoprostone 0.033 %w/w - dinoprostone - dinoprostone - for labour induction in term and near term pregnant women who have favorable induction features and who have a singleton pregnancy with vertex presentation

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - dinoprostone - ג'ל - dinoprostone 0.066 %w/w - dinoprostone - dinoprostone - for labour induction in term and near term pregnant women who have favorable induction features and who have a singleton pregnancy with vertex presentation

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - dinoprostone - תמיסה להזרקה - dinoprostone 10 mg/ml - dinoprostone - dinoprostone - therapeutic termination of pregnancy, missed abortion.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ethinylestradiol; gestodene - טבליות מצופות - ethinylestradiol 0.020 mg; gestodene 0.075 mg - gestodene and estrogen - gestodene and estrogen - contraceptive.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ethinylestradiol; gestodene - טבליות מצופות פילם - ethinylestradiol 0.015 mg; gestodene 0.06 mg - gestodene and estrogen - gestodene and estrogen - contraceptive.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - medroxyprogesterone acetate - תרחיף להזרקה - medroxyprogesterone acetate 150 mg/ml - medroxyprogesterone - medroxyprogesterone - for contraception where medically indicated and oral administration is inapplicable.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - medroxyprogesterone acetate - טבליה - medroxyprogesterone acetate 5 mg - medroxyprogesterone - medroxyprogesterone - in cases requiring progesterone supplement.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - medroxyprogesterone acetate - תרחיף להזרקה - medroxyprogesterone acetate 104 mg / 0.65 ml - medroxyprogesterone - medroxyprogesterone - * sayana is indicated for long-term female contraception. each subcutaneous injection prevents ovulation and provides contraception for at least 13 weeks (+/- 1 week). however, it should be taken into consideration that the return to fertility (ovulation) may be delayed for up to one year .since loss of bone mineral density may occur in females of all ages who use sayana long-term, a risk/benefit assessment, which also takes into consideration the decrease in bone mineral density that occurs during pregnancy and/or lactation, should be considered.* use in adolescents (12-18 years)in adolescents, use of sayana is only indicated when other contraceptive methods are considered unsuitable or unacceptable, due to unknown long-term effects of bone loss associated with sayana during the critical period of bone accretion.sayana has not been studied in women under the age of 18 years but data is available for intramuscular medroxyprogesterone acetate in this population.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ethinylestradiol; gestodene - טבליה - gestodene 0.075 mg; ethinylestradiol 0.030 mg - ethinylestradiol - ethinylestradiol - contraception.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - medroxyprogesterone acetate 100 mg - tablets - medroxyprogesterone - progestogen indicated for the treatment of certain hormone dependent neoplasms.